Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Margetuximab + Pembrolizumab in HER2+ Gastric/GEJ Cancer
NCT02689284Phase 2Completed
- Sponsor
- MacroGenics
- Start
- Jan 2016
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of margetuximab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by MacroGenics. Started Jan 2016; status: completed.
02
Drugs
margetuximab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT02689284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689284.